Company News
GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
Atlanta, GA, January 29, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the Company’s Board of Directors has approved a reverse stock split of its issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”), at a…
Read MoreAruna Bio Announces FDA Clearance of IND for Lead Program AB126, Enabling the First Exosome to Enter in Human Clinical Trials for a Neurological Indication
January 16, 2024 08:00 ET| Source: Aruna Bio BOSTON and ATHENS, Ga., Jan. 16, 2024 (GLOBE NEWSWIRE) — Aruna Bio, Inc., a pioneer in the development of neural exosome-based therapeutics for the treatment of neurodegenerative diseases, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of lead program,…
Read MoreGeorgia Bio, Nationwide Life Science Leaders Unite To Celebrate Continued Investment In Biotech At New York Stock Exchange
Industry leaders from across the country to ring NYSE closing bell and kick off Biotech Month FOR IMMEDIATE RELEASE January 4, 2024, New York, NY – Georgia Bio, the life sciences trade association in Georgia, joined 16 fellow life science trade organizations from across the country yesterday to ring the closing bell at the New…
Read MoreGeoVax Announces Issuance of Malaria Vaccine Patent
Patent Covers Multiple Component Vaccine for Both Prevention and Treatment Atlanta, GA, January 3, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issued Patent No. 11,857,611 to GeoVax, pursuant to the Company’s patent application No.…
Read MoreSIRPant Immunotherapeutics Announces FDA Clearance of IND Application for SIRPant-MTM for the Treatment of Solid Tumors
HUMMELSTOWN, Pa., Dec. 12, 2023 (GLOBE NEWSWIRE) — SIRPant Immunotherapeutics, Inc., a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for the Company’s lead product candidate, SIRPant-M™,…
Read MorePeter J. Arduini, President and CEO of GE HealthCare, Named Chair of AdvaMed Board of Directors
December 11, 2023 | WASHINGTON, D.C., – Today, AdvaMed, the Medtech Association, announced that Peter J. Arduini, president and CEO of GE HealthCare, will become the Chair of the AdvaMed Board of Directors. “The entire board and the global industry AdvaMed represents are very excited to have Peter as our new Board Chair during this critical…
Read MoreIndustry Leader and Globally Recognized Patient Advocate John F. Crowley Appointed to Lead BIO as President & CEO
Biotech entrepreneur, company founder, tireless patient advocate, and U.S. Navy combat veteran will guide the life science industry in its mission to feed, fuel and heal the world December 5, 2023 | The Biotechnology Innovation Organization (BIO) is proud to announce that industry leader and military veteran John F. Crowley will be its new President…
Read MoreMicron Biomedical Receives $23.6 Million to Accelerate Commercial Manufacturing of Needle-Free Vaccines and to Help Eradicate Measles
November 16, 2023 November 16 2023, ATLANTA– Micron Biomedical, a life science company developing first-in-class dissolvable microarray-based products that simplify and improve the transport, storage, and administration of drugs and vaccines, today announced a $23.6 million grant from the Bill & Melinda Gates Foundation that will fund mass production of needle-free vaccines. The manufacturing facility will…
Read MoreLife Science Nation bringing a medtech investor event to Atlanta in early 2024
In September, Life Science Nation announced “RESI South’ in partnership with a newly formed coalition of life science associations representing Alabama, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Virginia. The conference will come to Atlanta, GA, in [early] 2024. RESI South is expected to draw a crowd of over 500 bioscience and medtech entrepreneurs…
Read MoreFDA OKs Sanguina’s at-home test for anemia
People with anemia can now monitor levels of their hemoglobin with a simple test taken in the comfort of their homes. AnemoCheck Home, made by GRA-backed startup Sanguina, this month became the first at-home hemoglobin test kit to receive clearance by the U.S. Food and Drug Administration. Available only by prescription, the test involves a…
Read More